Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)

Next Previous
Trial Profile

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bepirovirsen (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms B Well 2
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 20 Sep 2024 Planned End Date changed from 28 Apr 2026 to 8 May 2026.
  • 13 Aug 2024 Planned End Date changed from 8 May 2026 to 28 Apr 2026.
  • 13 Aug 2024 Planned primary completion date changed from 24 Nov 2025 to 13 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top